# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-24-022025
Filing Date
2024-04-25
Accepted
2024-04-25 16:03:19
Documents
6
Period of Report
2024-06-05

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | ny20020644x1_def14a.htm | DEF 14A | 763596
2 |  | ny20020644x1_pc01.jpg | GRAPHIC | 614456
3 |  | ny20020644x1_pc02.jpg | GRAPHIC | 531913
4 |  | ny20020644x1_pvp01.jpg | GRAPHIC | 83041
5 |  | ny20020644x1_pvp02.jpg | GRAPHIC | 83152
6 |  | sig_douglaslove.jpg | GRAPHIC | 11471
| Complete submission text file | 0001140361-24-022025.txt |  | 2587053

Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39402 | Film No.: 24876135
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)